Dexlansoprazole MR for Treatment for Nocturnal Heartburn in Patients with Symptomatic Nonerosive GERD

Fass, Ronnie; Johnson, David A.; Orr, William C.; Pérez, Carolina Alejandra; Han, Cong; Mody, Reema; Stern, Kathleen

doi:10.14309/00000434-200910003-00029

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, once‐daily dosing with the enantiomer esomeprazole has demonstrated reductions in nighttime heartburn and GERD‐related sleep disturbances at 4 weeks compared to placebo in patients with GERD symptoms or a history of EE who demonstrated nighttime symptoms (Johnson et al, 2005). In addition, dexlansoprazole MR significantly increased the percentage of nights that patients diagnosed with symptomatic NERD were heartburn‐free compared to placebo (median of 73% vs. 36%, p < .001) when administered daily, in the morning without regard to meals (Fass et al, 2009). Patients who remain symptomatic while on once‐daily PPI therapy may be directed by a gastroenterologist to supplement with an OTC PPI or H2RA, double their once‐daily dosage, or take their prescribed PPI twice a day (Chey et al, 2009; Kahrilas et al, 2008).…”

Section: Improving Patient Outcomesmentioning

confidence: 99%

The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease

Friedlander¹,

Pallentino²,

Miller³

et al. 2010

Journal of the American Academy of Nurse Practitioners

View full text Add to dashboard Cite

GERD is commonly diagnosed and treated by nurse practitioners in the primary care setting. Acid suppression therapy is the primary medical therapy for GERD. PPI therapy provides symptomatic relief of heartburn and regurgitation, as well as effective healing and maintenance of erosive esophagitis. Newer PPIs lengthen the duration of acid suppression and allow for more flexibility in dosing, which may improve medication adherence and decrease episodes of acid breakthrough.

show abstract